Abstract
Exposure to stress is a major risk factor for the development of psychiatric disorders. Hence, stress-induced alterations represent an important target for pharmacological interventions aimed at restoring brain mechanisms that sustain pathologic alterations in affected individuals. In the present study, we used the chronic mild stress (CMS) paradigm that produces anhedonia, a core domain in psychiatric disorders, to investigate the ability of the antipsychotic drug lurasidone to counteract CMS-induced changes and to promote resilience.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
